Daily Anesthesiology Research Analysis
Analyzed 116 papers and selected 3 impactful papers.
Summary
A double-blind randomized trial found that continuous low-dose neostigmine reduced systemic inflammation and 28-day mortality in septic shock, supporting cholinergic anti-inflammatory pathway modulation. A rapid, species-independent SERS-based antimicrobial susceptibility test achieved 92% agreement within 5 hours on blood-culture isolates, enabling earlier targeted therapy. An intraoperative cohort analysis showed that cardiac power deficit predicted postoperative AKI primarily when oliguria was present, advocating hemodynamic management beyond MAP-centric metrics.
Research Themes
- Sepsis immunomodulation and cholinergic anti-inflammatory pathway
- Rapid, species-independent antimicrobial susceptibility testing
- Advanced intraoperative hemodynamic metrics and AKI risk
Selected Articles
1. Effect of Neostigmine on Attenuation of Proinflammatory Cytokines When Given as an Adjuvant Therapy in Septic Shock: A Randomized Control Trial.
In a double-blind RCT of septic shock patients, a 5-day neostigmine infusion (0.2 mg/h) significantly reduced TNF-α by day 5, lowered SOFA trajectories, and halved 28-day mortality compared with placebo. Findings support cholinergic anti-inflammatory pathway augmentation as an adjunctive sepsis therapy.
Impact: This is a rigorously designed RCT demonstrating mortality benefit from a widely available, low-cost drug via a defined immunomodulatory mechanism in septic shock.
Clinical Implications: Neostigmine infusion (0.2 mg/h for 5 days) could be considered as adjunct therapy in septic shock to attenuate systemic inflammation and potentially reduce mortality, pending multicenter replication and safety profiling.
Key Findings
- Day-5 TNF-α levels were significantly lower with neostigmine vs placebo (40±36 vs 67±43 pg/mL; p=0.002).
- Sequential Organ Failure Assessment (SOFA) scores decreased significantly from day 1 to day 5 in the neostigmine group (p<0.001).
- 28-day mortality was lower with neostigmine (26%) compared to control (54%; p=0.02).
Methodological Strengths
- Prospective, randomized, double-blinded, placebo-controlled design
- Pre-registered trial with clinically meaningful outcomes (28-day mortality) and biomarker endpoints
Limitations
- Single-center study limits generalizability
- Primary endpoint focused on cytokine reduction; mechanistic and safety profiles need broader validation
Future Directions: Multicenter RCTs to confirm mortality benefit, dose–response studies, and exploration of patient phenotypes most likely to benefit from cholinergic anti-inflammatory augmentation.
OBJECTIVE: The cholinergic anti-inflammatory pathway (ChAP) is the key regulator of the dysregulated cytokine storm in sepsis, with acetylcholine acting on alpha-7 nicotinic acetylcholine receptors (α7nAChRs) to suppress excessive inflammation. The objective of this study was to evaluate whether neostigmine administration modulates the inflammatory response in sepsis by enhancing cholinergic anti-inflammatory activity. DESIGN: A single-center, prospective, randomized, double-blinded, placebo-controlled study. SETTING: One adult ICU at a tertiary academic medical institution. INTERVENTION: Patients were randomized to receive neostigmine at a fixed rate of 0.2 mg/hr (2 mL/hr) or placebo. Study drug was administered for 5 days. MEASUREMENTS AND RESULTS: The primary outcome measure was decrease in tumor necrosis factor-alpha levels, in patients treated with neostigmine adjuvant therapy vs. the standard therapy. The secondary outcomes were hemodynamic parameters, septic shock reversal, changes in procalcitonin levels, and organ failure scores. The mean tumor necrosis factor-alpha levels were significantly lower in the neostigmine group (40 ± 36 pg/mL, mean ± sd) on day 5 as compared with the control group (67 ± 43 pg/mL; p = 0.002). There was a significant reduction in Sequential Organ Failure Assessment scores from day 1 to day 5 (p < 0.001) and 28-day mortality was also lower in the neostigmine group (26%) as compared with control group (54%, p = 0.02). CONCLUSIONS: The neostigmine infusion modulates the ChAP by potentiating the acetylcholine release leading to reduced systemic inflammation and decreased cytokine levels in septic shock patients. (Clinical Trial Registry of India number: CTRI/2023/07/ 055054).
2. SERS-Based Universal AST: Rapid Treatment Guidance for Blood-Culture Bacteria before Species Identification.
SERS-Uni-AST bypasses species identification and delivers antimicrobial susceptibility within 5 hours directly from blood-culture isolates, achieving 92% categorical agreement across 43 species and 7 antibiotics. The predefined, species-agnostic threshold performed robustly for Gram-positive and Gram-negative bacteria including ESKAPE pathogens.
Impact: A species-independent, label-free rapid AST shortens time-to-directed therapy for sepsis, potentially reducing mortality and antibiotic overuse.
Clinical Implications: Hospitals could implement SERS-Uni-AST in the microbiology workflow to guide earlier targeted antibiotics before species ID, complementing stewardship and Surviving Sepsis timeline targets.
Key Findings
- Achieved 92% categorical agreement with standard AST within 5 hours on 191 clinical isolates.
- Species-independent decision threshold enabled robust performance across 43 bacterial species and 7 antibiotics.
- Demonstrated applicability to both Gram-positive and Gram-negative bacteria, including ESKAPE pathogens.
Methodological Strengths
- Predefined, species-agnostic decision threshold validated across diverse clinical isolates
- Label-free, rapid metabolic readout leveraging SERS for broad applicability
Limitations
- No direct assessment of clinical outcomes such as time-to-effective therapy or mortality
- Requires blood culture positivity; performance on direct-from-blood specimens not evaluated
Future Directions: Prospective interventional studies to measure impact on time-to-directed therapy, mortality, and antimicrobial stewardship metrics; evaluation on direct-from-blood workflows.
Rapid antimicrobial susceptibility testing (AST) is essential for managing bloodstream infections with high mortality, yet most current methods require prior identification of bacterial species, limiting their speed and applicability. To address these limitations, we developed SERS-Uni-AST, a species-independent platform based on surface-enhanced Raman scattering (SERS) that monitors the metabolic responses of bacteria to antibiotics through label-free detection. This approach eliminates the need for species identification, simplifying the testing workflow, and expands applicability to rare or previously unknown bacterial species while significantly reducing turnaround time. Validated on 191 clinical blood-culture isolates encompassing 43 bacterial species and 7 clinically relevant antibiotics, SERS-Uni-AST achieved 92% categorical agreement with standard testing within 5 h. The method demonstrated robust performance across Gram-positive and Gram-negative bacteria, including ESKAPE pathogens, using a predefined, species-independent decision threshold. By enabling timely, susceptibility-guided antimicrobial therapy, SERS-Uni-AST supports early treatment optimization and aligns with the goals of the Surviving Sepsis Campaign and WHO antimicrobial stewardship initiatives.
3. Intraoperative oliguria modifies the association between cardiac power index and postoperative acute kidney injury: a retrospective cohort study.
In 814 adults undergoing non-cardiac surgery, the time below a CPI threshold (0.40 W/m²) predicted AKI only when intraoperative urine output was low, but not when urine output was ≥0.9 mL/kg/h. This interaction highlights the value of integrating flow-based metrics with urine output beyond MAP-centric strategies.
Impact: Introduces a physiologically integrative metric (CPI deficit) and demonstrates its AKI relevance conditional on oliguria, informing individualized intraoperative hemodynamic management.
Clinical Implications: Combine cardiac power and urine output to guide fluid/vasopressor/inotrope strategies; consider targets that restore both flow and output rather than MAP alone to mitigate AKI risk.
Key Findings
- AKI incidence was 7.2% (59/814).
- CPI time-deficit below 0.40 W/m² was associated with higher AKI risk only when urine output was low (<0.8 mL/kg/h).
- The interaction between CPI deficit and urine output was significant (aOR 0.97, 95% CI 0.93–0.99; P=0.03), and CPI deficit alone was significant only with the interaction model (aOR 1.05; P=0.004).
Methodological Strengths
- Use of time-integrated hemodynamic deficit metric (CPI0.4_AUT) capturing pressure-flow physiology
- Interaction modeling with urine output and multivariable adjustment
Limitations
- Retrospective, single-center design limits causal inference and generalizability
- CPI derived from FloTrac; potential measurement and model-specific biases
Future Directions: Prospective trials testing CPI- and urine output–guided hemodynamic protocols to reduce AKI; external validation across monitors and surgical populations.
PURPOSE: Postoperative acute kidney injury (AKI) is common and associated with adverse outcomes. Intraoperative hypotension and oliguria are risk factors, yet management remains mean arterial pressure (MAP)‑centric. Cardiac power index (CPI) may capture pressure-flow conditions, and its association with AKI may depend on intraoperative urine output. METHODS: We analyzed 814 adults undergoing non‑cardiac surgery with FloTrac™ monitoring. AKI was defined by the KDIGO creatinine criteria. The main predictors were CPI0.4_AUT, the time-integrated deficit of CPI below 0.40 W/m RESULTS: AKI occurred in 59 patients (7.2%). Without the interaction term, CPI0.4_AUT was not statistically significant at the 0.05 level (adjusted odds ratio [aOR] 1.02, 95% confidence interval [CI] 1.00-1.04, P = 0.10). With the interaction, CPI0.4_AUT was significantly associated with AKI (aOR 1.05, 95% CI 1.02-1.08, P = 0.004), and the CPI0.4_AUT × urine‑output term also reached significance (aOR 0.97, 95% CI 0.93-0.99, P = 0.03). Average marginal effects showed that higher CPI0.4_AUT was associated with a higher predicted AKI probability at low urine output (< 0.8 mL/kg/h), but this association was minimal when urine output was ≥ 0.9 mL/kg/h. CONCLUSIONS: Low intraoperative CPI with oliguria was associated with a higher predicted probability of AKI, whereas the CPI‑AKI association weakened with increased urine output. Integrating CPI and urine output may help characterize hemodynamic management beyond MAP‑centric management.